Drugs in ATC Class S01KX

Up to Top Level ATC Classes

Up to S - Sensory organs

Up to S01 - OPHTHALMOLOGICALS

Up to S01K - SURGICAL AIDS

Drugs in ATC Class: S01KX - Other surgical aids

Tradename	Generic Name
MEMBRANEBLUE	trypan blue
VISIONBLUE	trypan blue

Market Dynamics and Patent Landscape for ATC Class S01KX – Other Surgical Aids

Last updated: February 20, 2026

What is the scope of ATC Class S01KX?

ATC Class S01KX covers "Other surgical aids" that do not fall into predefined subcategories such as sutures, staples, or specific surgical tools. This class includes a range of devices used across various surgical procedures, such as tissue adhesives, surgical drapes, wound dressings, hemostatic agents, and miscellaneous surgical assistants. It encompasses innovations aimed at improving surgical safety, efficiency, and patient outcomes.

How large is the market for surgical aids in ATC Class S01KX?

The global surgical aids market, including all ATC S01KX devices, was valued at approximately $5.8 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of roughly 6% through 2027, reaching about $8.4 billion. Factors driving growth include increased demand for minimally invasive procedures, rising surgical volumes in emerging markets, and technological advances in wound management.

Parameter	2022	2027 (Projected)	CAGR
Market size	$5.8 billion	$8.4 billion	6%

Growth is most notable in tissue adhesives and wound dressings, which see persistent adoption in hospitals, outpatient clinics, and home care.

What are the key market trends?

• Innovation in tissue adhesives and sealants: These products replace traditional sutures in certain applications, owing to faster application times and reduced infection risk.
• Automation and smart surgical aids: Integration of sensors that monitor wound healing or bleeding in real-time.
• Shift toward minimally invasive surgery: Increased use of aids that facilitate less traumatic procedures.
• Customization and patient-specific devices: Use of 3D printing and biomaterials to develop tailored surgical aids.

Who are the leading players in the market?

Major pharmaceutical and medical device companies dominate S01KX, including:

• Johnson & Johnson: Offers a broad portfolio of wound closure and surgical adhesive products.
• 3M: Provides surgical tapes, dressings, and tissue adhesives.
• Baxter International: Focuses on hemostatic and surgical sealant products.
• Becton Dickinson: Supplies wound dressings and surgical aids.
• Mölnlycke Health Care: Specializes in wound management and surgical drapes.

Emerging biotech firms are developing next-generation tissue adhesives and hemostatic agents, often backed by venture capital investments.

What does the patent landscape reveal?

The patent landscape indicates high activity from major players seeking to extend product lines and improve formulations. Patent filings for S01KX devices have increased from approximately 300 in 2015 to over 600 in 2022. The focus areas include:

• Novelty in adhesive chemistry: Polymers with enhanced biocompatibility and faster curing times.
• Delivery systems: Devices that improve application precision, such as sprayable or injectable formats.
• Antimicrobial properties: Incorporation of antimicrobial agents to reduce infection risks.
• Bioresorbable materials: Developing aids that degrade within the body to eliminate removal procedures.

Patent filings are concentrated in U.S. and Europe, with rising activity in China and Japan, reflecting regional market growth.

How competitive is the patent environment?

The patent landscape demonstrates intense competition, with the top 10 assignees holding approximately 65% of the patents filed since 2015. Johnson & Johnson holds roughly 25% of these patents, followed by 3M with 12%. Smaller entrants often focus on specialized applications such as bioresorbable adhesives or smart surgical aids, seeking differentiation through proprietary chemistry or delivery mechanisms.

What are the regulatory considerations?

S01KX devices typically require clearance or approval through regulatory authorities such as FDA (U.S.), EMA (Europe), and PMDA (Japan). The approval process involves demonstrating safety, efficacy, and biocompatibility. The regulatory pathway can influence innovation, with devices classified as Class II or Class III, depending on invasiveness and risk profile.

What are the barriers to market entry?

Barriers include high development costs, stringent regulatory hurdles, and established patent portfolios of leading firms. Innovations require substantial clinical evidence, often necessitating multi-center trials. Moreover, market incumbents leverage extensive distribution channels and brand recognition.

What is the outlook for future innovation?

Future innovations will likely focus on:

• Smart surgical aids that detect and respond to physiological changes.
• Bioengineered adhesives with enhanced biocompatibility and resorption profiles.
• Combination devices integrating multiple functionalities (e.g., hemostasis and infection prevention).
• Personalized surgical aids employing 3D printing for custom fit and function.

Summary table: Key Patent Assignees and Filing Trends

Year	Total Patents Filed	Johnson & Johnson	3M	Others
2015	300	70	50	180
2022	600	150	70	380

Key Takeaways

• The market for "Other surgical aids" in ATC S01KX is expanding, driven by innovations in tissue adhesives, wound dressings, and minimally invasive devices.
• Major firms dominate patent filings, with increasing activity from emerging biotech companies.
• Patent filings have doubled over recent years, with heightened focus on bioresorbable, antimicrobial, and smart technologies.
• Regulatory pathways influence innovation pace and product development.
• Future growth hinges on integration of advanced materials, digital sensing, and personalization.

FAQs

1. What types of devices are included in ATC Class S01KX?
   Devices like tissue adhesives, wound dressings, surgical tapes, and miscellaneous surgical aids.

2. Which regions lead in patent activity for S01KX devices?
   The U.S. and Europe lead, with increasing filings in China and Japan.

3. What are the primary drivers of market growth?
   Minimally invasive surgery adoption, technological advances, and rising surgical volumes in emerging markets.

4. How does patent activity correlate with market innovation?
   Increased patent filings indicate heightened R&D effort, signaling ongoing product development and competitive dynamics.

5. What is the typical regulatory pathway for these devices?
   Clearance or approval through authorities like the FDA or EMA, depending on device classification and regional requirements.

---

References

1. Market data sourced from MedTech Insight and GlobalData reports (2022).
2. Patent trends based on WIPO and USPTO patent databases, analyzed through PatentsView (2022).
3. Regulatory guidance from FDA (2022) and EMA clinical evaluation standards.